Cargando…
Patients with NSCLC may display a low ratio of p.T790M vs. activating EGFR mutations in plasma at disease progression: implications for personalised treatment
INTRODUCTION: NSCLC harboring activating mutations of EGFR is highly sensitive to first-line EGFR-tyrosine kinase inhibitors (TKIs), but drug resistance depending on the EGFR mutation p.T790M will occur in about 50-60% of patients. Detailed information on the amount of p.T790M plasmatic level associ...
Autores principales: | Del Re, Marzia, Bordi, Paola, Petrini, Iacopo, Rofi, Eleonora, Mazzoni, Francesca, Belluomini, Lorenzo, Vasile, Enrico, Restante, Giuliana, Di Costanzo, Francesco, Falcone, Alfredo, Frassoldati, Antonio, van Schaik, Ron H.N., Steendam, Christi M.J., Chella, Antonio, Tiseo, Marcello, Morganti, Riccardo, Danesi, Romano |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5689667/ https://www.ncbi.nlm.nih.gov/pubmed/29156777 http://dx.doi.org/10.18632/oncotarget.20947 |
Ejemplares similares
-
The amount of activating EGFR mutations in circulating cell-free DNA is a marker to monitor osimertinib response
por: Del Re, Marzia, et al.
Publicado: (2018) -
Implications of KRAS mutations in acquired resistance to treatment in NSCLC
por: Del Re, Marzia, et al.
Publicado: (2017) -
Contribution of KRAS mutations and c.2369C > T (p.T790M) EGFR to acquired resistance to EGFR-TKIs in EGFR mutant NSCLC: a study on circulating tumor DNA
por: Del Re, Marzia, et al.
Publicado: (2016) -
The increase in activating EGFR mutation in plasma is an early biomarker to monitor response to osimertinib: a case report
por: Del Re, Marzia, et al.
Publicado: (2019) -
Understanding the Mechanisms of Resistance in EGFR-Positive NSCLC: From Tissue to Liquid Biopsy to Guide Treatment Strategy
por: Del Re, Marzia, et al.
Publicado: (2019)